The Use of Protease Inhibitors in Pregnancy: Maternal and Fetal Considerations

Table 1

Population characteristics in HIV-infected pregnant women by type of antepartum antiretroviral therapy.

	ART with a protease inhibitor	ART without a protease inhibitor	No ART	value
Race/ethnicity					0.5
Black	413 (69)	154 (67)	114 (64)
Hispanic	112 (19)	43 (19)	33 (19)
White	68 (11)	33 (14)	28 (16)
Other	4 (1)	0 (0)	2 (1)
Nulliparity	183 (31)	75 (33)	79 (45)	0.005
Age at delivery, years	27.5 ± 5.9	25.7 ± 7.4	24.7 ± 6.3	<0.001
Gestational age at presentation for prenatal care, weeks	12 8, 21	13.5 9, 22	23.5 13, 34	<0.001

Data reported as mean ± SD, median quartiles, or (%) as appropriate.